619 related articles for article (PubMed ID: 21362264)
1. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
4. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
[TBL] [Abstract][Full Text] [Related]
7. What biologic factors predict for transformation to AML?
Bejar R
Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
9. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
12. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
13. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
15. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
Sill H; Zebisch A; Haase D
Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
[TBL] [Abstract][Full Text] [Related]
16. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
17. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
18. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
19. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]